

Biocon*(FDA, Approval)*

Biocon receives approval from FDA for YESINTEK 45 mg/0.5 mL and 90 mg/mL single-dose prefilled autoinjectors to treat adult and pediatrics with psoriasis, and adults with CD and UC

Regeneron*(FDA, Approval)*

Regeneron gets FDA approval for PASATRU, indicated to reduce the formation of new HO lesions and clinician-assessed flare-ups in adults with FOP

Ultragenyx*(FDA, Accelerated Approval)*

FDA grants accelerated approval for Ultragenyx's DTX401, indicated to treat GSDIa in adults and pediatrics

Johnson&Johnson*(EU, Approval)*

J&J receives indication extension approval from EC for TECVAYLI in combination with daratumumab to treat adults with RRMM who received at least one prior therapy



●► **Acadia** *(EU, Approval)*

EC approves Acadia's DAYBU to treat neurobehavioral symptoms of Rett syndrome in people aged five years and older

●► **Teva** *(FDA, Priority Review)*

Teva obtains priority review from the FDA for ecopipam to treat pediatric patients with Tourette syndrome

●► **GSK** *(FDA, Priority Review)*

FDA accepts GSK's sBLA for JEMPERLI and granted it priority review for patients with previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer

●► **Faeth** *(FDA, Fast Track)*

Faeth gains FDA Fast Track designation for PIKTOR plus paclitaxel to treat biomarker-selected advanced or recurrent endometrial cancer



●▶ Lupin*(Collaboration)*

VISUfarma, a Lupin subsidiary, collaborates with Visus Therapeutics to commercialize and distribute YUVEZZI, indicated for adult presbyopia across the EU and UK

●▶ Sandoz*(Collaboration)*

Sandoz collaborates with Henlius to develop 10 biosimilars, expanding its pipeline for USD 322M

●▶ Chugai Pharmaceutical*(Collaboration)*

Chugai Pharmaceutical collaborates with GSK to develop, manufacture and commercialize AID351 for the management of flavivirus infections, including dengue fever

●▶ Argenx*(Phase 3, Results)*

Argenx's Ph3 ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis demonstrates improvement in TIS score at Week 52 vs. placebo



► HUTCHMED*(Phase 3, Results)*

HUTCHMED's Ph3 SAFFRON trial evaluating ORPATHYS plus TAGRISSO in EGFRm NSCLC patients with MET resistance demonstrates improvement in PFS and OS vs. platinum-based chemotherapy

► Moderna*(Phase 3, Results)*

Merck and Moderna's Ph3 INTerpath-001 trial evaluating V940 in combination with KEYTRUDA met its endpoints of RFS and DMFS in patients with completely resected stage IIB-IV melanoma over treatment with KEYTRUDA alone

